---
schema_version: "secwatch.filing_event.v1"
accession: "0001703057-25-000024"
form_type: "8-K"
ticker: "ABCL"
cik: "0001703057"
company_name: "AbCellera Biologics Inc."
filed_at: "2025-11-06T23:59:59+00:00"
generated_at: "2026-05-16T23:48:30.786972+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# AbCellera Q3 net loss widens to $57.1M; revenue rises to $9.0M

## Summary
- Net loss of $57.1M ($0.19/share) vs $51.1M ($0.17/share) in Q3 2024.
- Total revenue $9.0M, up from $6.5M in Q3 2024.
- Appointed Sarah Noonberg, M.D., Ph.D., as Chief Medical Officer.
- Cumulative partner-initiated program starts with downstreams: 103; molecules in clinic: 18.
- Total available liquidity $680M ($523M cash/securities + $159M non-dilutive funding).

## SEC filing metadata
- accession: 0001703057-25-000024
- form_type: 8-K
- ticker: ABCL
- cik: 0001703057
- company_name: AbCellera Biologics Inc.
- filed_at: 2025-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1703057/000170305725000024/0001703057-25-000024-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1703057/000170305725000024/abcl-20251106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001703057-25-000024
- JSON: https://secwatch.observer/filing/0001703057-25-000024.json
- Plain text: https://secwatch.observer/filing/0001703057-25-000024.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.